In the realm of medical research, few stories are as inspiring as the one emerging from the collaboration between parents, charities, and academics in the pursuit of groundbreaking treatments for rare diseases. One such remarkable tale involves the discovery of a potential cure for DHDDS, a severe neurodegenerative condition that affects children, using a cutting-edge technique known as lab-grown mini brains. This is not just a scientific breakthrough; it's a testament to the power of human ingenuity and the potential for personalized medicine.
A Rare Condition, A Dire Situation
DHDDS, or Dolichol Deficiency Disease, is a rare genetic disorder that manifests in early childhood, causing tremors, seizures, coordination and learning difficulties. Until recently, parents were told that there was little they could do to slow its progression. The condition is so rare that it often went undiagnosed, leaving families with a sense of helplessness and despair. But all of that changed when researchers began to explore innovative ways to understand and treat the disease.
The Power of Mini Brains
Dr. Irena Muffels, a clinical genetics resident at the Wilhemina Children's Hospital in Utrecht, The Netherlands, played a pivotal role in this story. She recalls the moment when two parents, desperate for a solution, contacted her and Professor Eva Morava at the Icahn School of Medicine at Mount Sinai, New York. They had been told that their children's only hope was to wait for researchers to take an interest in the rare disorder. But these parents were determined not to wait.
"They didn't want their children to become wheelchair-dependent and unable to take care of themselves due to their movement problems," Dr. Muffels explains. "So they contacted us, and we started creating mini-brains - tiny blobs of brain tissue grown in the lab from patients' own cells." This approach not only avoided the need to take samples directly from the children's brains but also provided a powerful tool for understanding the disease mechanism.
Unraveling the Disease Mechanism
The mini-brains, derived from the patients' cells, revealed crucial insights into the disease. After four months, the mini-brains showed clear signs of deterioration, mirroring what happens in real patients. The researchers found that the DHDDS gene helps produce dolichol, a small lipid 'anchor' that carries sugar. In the mini-brains, they discovered that this anchor was severely reduced, leading to mistakes in the building of glycans, which are essential for proteins to perform their correct functions.
Another critical finding was the impact of defective DHDDS on lipid metabolism. Reduced dolichol can lead to significant cholesterol build-up in astrocytes, brain cells involved in neuroprotection. "This accumulation builds over time, and this is why we think the disease progresses," Dr. Muffels explains. "Since the accumulation of cholesterol leads to mitochondrial dysfunction, leading in turn to reduced energy production."
A Promise of Hope: NMN
The researchers, in collaboration with the biotech company Perlara, screened FDA-approved drugs and vitamins to identify potential new therapies. They found that NMN, a naturally-occurring form of vitamin B3, was able to rescue a yeast model of DHDDS-related disease. When tested in the mini-brains, NMN showed striking improvements. Since NMN can be bought without a prescription, some patients started ordering it online before the experiments were completed.
"Within a month, we noticed that these patients' walking improved and that they were more energetic, less shaky, and their movements became more fluid. It really seemed to slow down the progression of the disease," Dr. Muffels says. "NMN has been shown to improve molecular mechanisms in muscle cells of patients with mitochondrial disease, a common and devastating pediatric metabolic disorder. High doses of the vitamin have also been shown to slow progression in Parkinson's disease patients and reduce symptom burden."
A Global Effort for a Global Impact
The word about NMN spread among DHDDS patients, and Dr. Muffels now has 12 patients taking it. With funding from CDG UK, the national charity supporting those affected by Congenital Disorders of Glycosylation (CDG), an international trial for NMN supplementation in DHDDS-related disease is underway. "There is still a long way to go," Dr. Muffels acknowledges, "but it was encouraging to see how well the creation of the mini-brains helped us mimic the progression of the disease in patients."
A Brighter Future for Rare Diseases
This study is a perfect example of how rapid progress in genetic diagnosis can lead to new treatments for rare diseases. Because rare diseases like DHDDS affect so few people, it is usually very difficult to get industry interested. But in this case, a united front of parents, charities, and academics was able to find a promising therapy that is also cheap and widely available. This is a powerful reminder that with determination and innovation, even the rarest of conditions can be tackled, offering hope and a brighter future for those affected.
